Gilead says, “Remdesivir, our investigational antiviral medicine, is currently given to patients intravenously through daily infusions in the hospital. An inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside the hospital, at earlier stages of disease. That could have significant implications in helping to stem the tide of the pandemic.” Here’s the companies full statement:

We are continuing to explore the full potential of our investigational antiviral for the treatment of COVID-19. Read more from our Chairman and CEO Daniel O’Day about the next wave of studies and our efforts to increase supply and ensure access.

— Gilead Sciences (@GileadSciences) June 22, 2020